Divi's Laboratories reported Q3FY26 results with a PAT of ₹583 crore, slightly down from ₹589 crore year-over-year. Total ...

Management said operational metrics improved during the quarter despite near-term revenue softness and indicated that growth drivers remain intact.

The Hyderabad-based company's consolidated net profit marginally fell to ₹583 crore ($64.31 million) in the quarter ended December 31, from ₹589 crore a year earlier ...

The ever-popular scalp serum and root touch-up are now at a reduced price point, but it won’t last for long. The serum has earned rave reviews from me in particular, with the viral scalp serum also ...

Prabhudas Lilladher recommended accumulate rating on Divis Laboratories with a target price of Rs 6850 in its research report ...

Divi's Labs reported a weaker-than-expected set of headline numbers on Wednesday.

Net profit for the December quarter fell 1 percent year‑on‑year to Rs.583 crore, compared with Rs.589 crore a year earlier, weighed down by a Rs.74‑crore exceptional charge arising from India’s newly ...

Murali Divi, the founder of Divi’s Labs, one of the top three manufacturers of active pharmaceutical ingredients (API) belongs to a small town in Andhra Pradesh. With his hard work, he established a ...

Feb 11 (Reuters) - Indian contract drug manufacturer Divi's Laboratories reported third-quarter profit below estimates on Wednesday, as high raw material costs and a one-off charge due to changes in ...